Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Pharmacopeia to Request a Hearing With NASDAQ Following Receipt of Notice of Non-Compliance
Pharmacopeia Announces Third Quarter 2008 Financial Results
Ligand and Pharmacopeia to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Ligand and Pharmacopeia to Present At the Oppenheimer 19th Annual Healthcare Conference
Pharmacopeia Receives Notification From NASDAQ
Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights - PrimeZone
Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights - Business Wire
Pharmacopeia and GlaxoSmithKline Collaboration Identifies Sixth Lead Compound
Pharmacopeia Announces Further Reductions to Workforce
Pharmacopeia Announces Second Quarter 2008 Financial Results
Pharmacopeia to Present At the Canaccord Adams 28th Annual Global Growth Conference
Pharmacopeia Earns Milestone Payment From Wyeth
Pharmacopeia Advances Therapeutic Program With GlaxoSmithKline
Pharmacopeia to Present At the BMO Capital Markets 8th Annual Focus On Healthcare Conference
Pharmacopeia to Host Second Quarter 2008 Financial Results Webcast and Conference Call
Pharmacopeia and GlaxoSmithKline Collaboration Identifies a New Lead Compound
Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
BellwetherReport.com Analyst Report on FLEX, PCOP, URBN and KSS - May 27 2008 1:25AM
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients - May 27 2008 12:55AM
Pharmacopeia Announces First Quarter 2008 Financial Results - Jun 2 2008 1:28AM
Pharmacopeia to Host First Quarter 2008 Financial Results Webcast and Conference Call
Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
